

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

U.S.PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5306817		1994-04-26	Thiruvengadam et al.	
	2	5846966		1998-12-08	Rosenblum et al.	
	3	5767115		1998-06-16	Rosenblum et al.	
	4	5631365		1997-05-20	Rosenblum et al.	
	5	5739321		1998-04-14	Wu et al.	
	6	5886171		1999-03-23	Wu et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
-------------------	---------	--------------------	------------------------	------------------	---	--

/Mark Berch/ (02/05/2008)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

1						
---	--	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0250060	WO		2002-06-27	Avantis Pharma Deutschland GMB		<input type="checkbox"/>
	2	0250068	WO		2002-06-27	Aventis Pharma GMBH		<input type="checkbox"/>
	3	0250027	WO		2002-06-27	Aventis Pharma GMBH		<input type="checkbox"/>
	4	0218432	WO		2002-03-07	Aventis Pharma GMBH		<input type="checkbox"/>
	5	02066464	WO		2002-08-29	Noda Atsushi et al.		<input type="checkbox"/>
	6	524595	EP		1993-01-27	Schering Corporation		<input type="checkbox"/>
	7	9414433	WO		1994-07-07	Schering Corporation		<input type="checkbox"/>
	8	95/01961	WO		1995-01-19	Schering Corporation		<input type="checkbox"/>

/Mark Berch/ (02/05/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor	Ingemar Starke	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	133087.07001	

9	9609827	WO		1996-04-04	Pfizer Inc.		<input type="checkbox"/>
10	9745406	WO		1997-12-04	Schering Corporation		<input type="checkbox"/>
11	0020623	WO		2000-04-13	Schering Corporation		<input type="checkbox"/>
12	0034240	WO		2000-06-15	Schering Corporation		<input type="checkbox"/>
13	0038725	WO		2000-07-06	G.D. Searle & Co.		<input type="checkbox"/>
14	0060107	WO		2000-10-12	Schering Corporation		<input type="checkbox"/>
15	0063703	WO		2000-10-26	Schering Corporation		<input type="checkbox"/>
16	02072104	WO		2002-09-19	Merck & Co., Inc.		<input type="checkbox"/>
17	02058685	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
18	02058696	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
19	02058731	WO		2008-08-01	Schering Corporation		<input type="checkbox"/>

/Mark Berch/ (02/05/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

20	02058732	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
21	02058733	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
22	02058734	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
23	02079174	WO		2002-10-10	Schering Corporation		<input type="checkbox"/>
24	02096415	WO		2002-12-05	Schering Corporation		<input type="checkbox"/>
25	03026644	WO		2003-04-03	Schering Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Clader et al., "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus," J. Med Chem (1996) 39:3684-3693.	<input type="checkbox"/>
	2	McKittrick et al., "Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.	<input type="checkbox"/>
	3	Burnett et al., "2-Azetidinones as Inhibitors of Cholesterol Absorption," J. Med Chem (1994) 12:1733-1736.	<input type="checkbox"/>

/Mark Berch/ (02/05/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

4	Castaner et al., "Ezetimibe," Drugs of the Future (2000) 25(7):679-685.	<input type="checkbox"/>
5	Vaccaro et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification of the sugar," Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.	<input type="checkbox"/>
6	Fu et al., "Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS catalyzed ketone reduction," Tetrahedron Letters (2003) 44:801-804.	<input type="checkbox"/>
7	Kirkup et al., "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor," Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.	<input type="checkbox"/>
8	Vaccaro et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors," Bioorganic & Medicinal Chemistry Letters (1998) 8:319-322.	<input type="checkbox"/>
9	Rosenblum et al., "Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 - hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.," J. Med Chem (1998) 41:973-980.	<input type="checkbox"/>
10	Wu et al., "A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors," J. Org. Chem (1999) 64:3714-3718.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Mark Berch/ (02/05/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.